Please login to the form below

Not currently logged in
Email:
Password:

non-steroidal therapy

This page shows the latest non-steroidal therapy news and features for those working in and with pharma, biotech and healthcare.

Roche out-licenses lebrikizumab rights to Dermira

Roche out-licenses lebrikizumab rights to Dermira

Other competition is also in the offing including GlaxoSmithKline's asthma therapy Nucala (mepolizumab) and non-steroidal anti-inflammatory tapinarof, which are both in mid-stage testing for atopic dermatitis, and

Latest news

  • FDA green light for Pfizer's eczema drug FDA green light for Pfizer's eczema drug

    Pfizer's blockbuster-in-waiting Eucrisa has been approved by the FDA for eczema, becoming the first non-steroidal therapy for the skin condition in more than 15 years.

  • Pfizer adds eczema drug with $5.2bn Anacor acquisition Pfizer adds eczema drug with $5.2bn Anacor acquisition

    Pfizer adds eczema drug with $5.2bn Anacor acquisition. Expands innovative products business with non-steroidal therapy Crisaborole. ... and if approved would be the first new non-steroidal therapy for the skin condition in more than 15 years.

  • Novartis wins childhood arthritis indication for Ilaris in EU Novartis wins childhood arthritis indication for Ilaris in EU

    Ilaris gains a new indication as a monthly subcutaneous injection in patients aged two years and older who have not responded to therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and ... The approval] represents another significant milestone in

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics